Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.

Warsame R, Bang SM, Kumar SK, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Rajkumar SV, Dispenzieri A.

Eur J Haematol. 2014 Jun;92(6):485-90. doi: 10.1111/ejh.12282. Epub 2014 Mar 2.

PMID:
24502602
2.

Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.

Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK.

Am J Hematol. 2017 Jun;92(6):549-554. doi: 10.1002/ajh.24723. Epub 2017 Apr 26.

PMID:
28314084
3.

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.

Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK.

Leuk Lymphoma. 2010 Dec;51(12):2181-7. doi: 10.3109/10428194.2010.524329. Epub 2010 Oct 20.

PMID:
20958232
4.

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.

Cibeira MT, Oriol A, Lahuerta JJ, Mateos MV, de la Rubia J, Hernández MT, Granell M, Fernández de Larrea C, San Miguel JF, Bladé J; PETHEMA cooperative study group.

Br J Haematol. 2015 Sep;170(6):804-13. doi: 10.1111/bjh.13500. Epub 2015 May 14.

PMID:
25974382
5.

Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.

Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A.

Blood. 2017 Sep 28;130(13):1578-1584. doi: 10.1182/blood-2017-05-783415. Epub 2017 Aug 14.

PMID:
28807981
6.

Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.

Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Kumar SK, Leung N, Lust J, Rajkumar SV, Russell SJ, Suman VJ, Le-Rademacher JG, Hogan WJ.

Cancer. 2016 Jul 15;122(14):2197-205. doi: 10.1002/cncr.30051. Epub 2016 May 3.

7.

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.

PMID:
15566357
8.

Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.

Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Foard D, Roussel M, Rannigan L, Gibbs SDj, Pinney JH, Whelan CJ, Lachmann HJ, Hawkins PN, Wechalekar AD.

Haematologica. 2014 Dec;99(12):e260-3. doi: 10.3324/haematol.2014.108191. Epub 2014 Sep 5. No abstract available.

9.

Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.

Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N.

Nephrol Dial Transplant. 2011 Jun;26(6):2032-6. doi: 10.1093/ndt/gfr067. Epub 2011 May 4.

PMID:
21543655
10.

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1413-7. doi: 10.1016/j.bbmt.2015.03.025. Epub 2015 Apr 2.

11.

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.

Br J Haematol. 2007 Oct;139(2):224-33.

PMID:
17897298
12.

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P.

J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14.

13.

Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis.

Nelson LM, Gustafsson F, Gimsing P.

Acta Haematol. 2015;133(4):336-46. doi: 10.1159/000363682. Epub 2014 Dec 16.

PMID:
25531398
14.

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.

Vesole DH, Pérez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Mayo Clin Proc. 2006 Jul;81(7):880-8.

PMID:
16835967
15.

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.

16.

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.

Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Eur J Haematol. 2016 Oct;97(4):342-7. doi: 10.1111/ejh.12736. Epub 2016 Feb 15.

PMID:
26773409
17.

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M.

Blood. 2011 Oct 20;118(16):4346-52. doi: 10.1182/blood-2011-01-330738. Epub 2011 Aug 9.

18.

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.

19.

Autologous stem cell transplantation and IgM amyloidosis.

Valente M, Roy V, Lacy MQ, Dispenzieri A, Gertz MA.

Leuk Lymphoma. 2006 Jun;47(6):1006-12.

PMID:
16840189
20.

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.

Bone Marrow Transplant. 1997 Jul;20(1):21-6.

Supplemental Content

Support Center